Cenedella.de

Philman's Pharm: "German Quality, California Ingenuity." Est. 1977


1 Comment

GERMAN PATIENT ROUNDTABLE announces Educational event scheduled for Oct. 19th in Berlin.

The cannabis patient Consultation  – information Evening (Part 1)

“Where can I find reliable information about” Medical cannabis “? My previous medications have hardly any effect and sometimes strong side effects. What can I do as a patient? ”

Cannabis as a medicine is gaining more and more acceptance in our society. Nevertheless, obtaining this prescriptive medicine is still associated with some bureaucratic and reputational hurdles. Stigma and social prejudice make doctors shy away and potential patients remain helpless. The German Patient Roundtable brings together the various stakeholders, provides active assistance and promotes dialogue between patients, doctors, research and industry.

The aim of the German Patient Roundtable is to bring together, network and inform patient interests in order to optimally care for them. Through active action, the above-mentioned hurdles should be eliminated and more patients should be informed about the possibility of treatment with cannabinoids.

The event on October 19th highlights cannabis as a medicine and provides helpful information, especially for (potential) patients. The symposium looks at four perspectives:

1. Advocacy: People who are committed to patients.

2. Science: People who are researching and actively working on cannabinoids.

3. Medicine: people who actively treat with cannabinoids in medical practice.

4. Patients: People who want to be treated or are treated with “Medical Cannabis”.

This event is the first in a presumably four-part series of events. The second appointment is planned for January 18th 2019.

*: The event is an information evening. There is no medical consultation (by doctors)

 

MORE INFO AT:    Oct. 19th event


German cultivation tender for medical marijuana stopped in its tracks…..and information on the GERMAN PATIENT ROUNDTABLE www.germanpatientroundtable.de

https://www.cannabisindustryjournal.com/news_article/german-court-stops-pending-cannabis-cultivation-bid-on-technical-fault/

German Patients are Going to be on the Front Lines of This Discussion

The difficulties that German patients have already faced in obtaining a drug that is now legal in their own country for medical use (and even for recreational purposes across an open border in Holland) are legion. While to a certain extent, German patients are in the same boat as patients elsewhere and their problems, in fact, there are still huge access issues that remain. For starters, the drug is much more expensive here, so those without health insurance approval face bills of about $3,000 per month. Why the eye-watering price? All medical grade cannabis is still imported, although increasingly this is now just via other EU countries, not just from Canada.

“One of the reasons we organized the national German Patient Roundtable is to give patients a voice in all of this supply and demand discussion and to help BfArM and others formulate workable solutions for all,” responded Philip Cenedella IV when reached for a response by CIJ. Cenedella, an American expat and the organizer of the Roundtable, a nationally focussed, umbrella group that is kicking off its campaign this year, spoke for many who are far from court and boardrooms where the decisions are being made.

Philip Cenedella
Philip Cenedella, pictured left, at the Deutsche Hanfverband (DHV) conference in Berlin last November.
Photo: @MedPayRx, Instagram

“While there are very talented firms who will now take up this discussion with the government and reissue a response for the tender, what we continue to see on the ground is that patients simply do not have the access granted them in the law which was passed over a year ago,” Cenedella says, with more than a note of frustration. “We again are calling on all government officials, industry executives and patient advocates to band together to immediately establish workable protocols that directly help the patients.”

Indeed, despite the frustration and delay, if not new costs and opportunities that this decision creates, one thing is very clear on the ground here. The current status quo is unacceptable. That alone should also put pressure on the powers that be to remedy the situation as quickly as possible. And via several routes, including widening import quotas or even issuing new licenses as a new solution to domestic cultivation is implemented.

“Patients are not being served and do not have access to a medicine that has been proven to improve lives,” says Cenedella. “Our simple request is for BfArM to finally invite patients into their discussions, to work with patients to formulate workable cultivation and distribution solutions, and we humbly request that this happen now before they go down another dead-end road, ending in another court defeat, and resulting in even more delays to the patients that are still lacking the care afforded them by the German Federal Court’s decision of 2017.”

 

For more info:

http://www.germanpatientroundtable.de